GLPwatch
Soliqua for Alzheimer's disease
lixisenatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCSoliqua (lixisenatide) is not FDA-approved for Alzheimer's disease, and any use for this condition is off-label or investigational. Research in animal models suggests lixisenatide may have neuroprotective effects and reduce Alzheimer's-related pathology, but these findings have not been confirmed in humans.
AI summary of the sources below.
| Drug | Soliqua (lixisenatide) |
|---|---|
| Condition | Alzheimer's disease |
| Approval status | Investigational / off-label |
| Research papers | 7 |
Soliqua is not FDA-approved for alzheimer's disease; the research below reflects investigational or off-label study only.
Research on lixisenatide for alzheimer's disease (7)
- Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.
- Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease.
- Lixisenatide rescues spatial memory and synaptic plasticity from amyloid β protein-induced impairments in rats.
- Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease.
- Lixisenatide improves recognition memory and exerts neuroprotective actions in high-fat fed mice.
- Lixisenatide attenuates the detrimental effects of amyloid β protein on spatial working memory and hippocampal neurons in rats.
- Lixisenatide Reduced Damage in Hippocampus CA1 Neurons in a Rat Model of Cerebral Ischemia-Reperfusion Possibly Via the ERK/P38 Signaling Pathway.